Project Grant R16AI200913
Award Date 8/1/26
Completion Date 7/31/30
Dollars Obligated $143K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Johnson City, TN 37614, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded the University of Tennessee Health Science Center $163,852 on November 1, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct research on the septation initiation network (SIN) kinase cascade in Aspergillus fumigatus, with the goal of enhancing echinocandin antifungal efficacy against invasive pulmonary aspergillosis. The research interrogates SIDB-dependent septation mechanisms that confer...
- The National Institute of Allergy and Infectious Diseases awarded the University of Tennessee Health Science Center $678,934 on July 22, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate novel host-adaptation mechanisms regulating Aspergillus fumigatus pathogenic fitness in invasive aspergillosis. The recipient will conduct basic science research identifying and characterizing new antifungal targets for invasive mold infection caused by A. fumigatus,...
- The National Institute of Allergy and Infectious Diseases awarded the University of Tennessee $230,313 on August 19, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop a genome-wide CRISPR screening platform in diploid Candida albicans for identifying mechanisms of antifungal resistance. The project will create tools for efficient DNA transformation and CRISPR-based genome editing in C. albicans, then apply these tools to perform genome-wide screening to...
- The National Institute of Allergy and Infectious Diseases awarded Texas A&M University System Health Science Center $192,500 on June 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) for research into novel antifungal therapeutics. The award funds structure-based design, synthesis, and validation of small molecule inhibitors targeting fungal SEC14 phosphatidylinositol transfer proteins as a strategy to combat multi-drug-resistant fungal infections,...
- The National Institute of Allergy and Infectious Diseases awarded the University of Texas Health Science Center at Houston $429,000 on February 2, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct spatial analysis of gene expression in fungal infections. The research applies spatial transcriptional analysis to host-pathogen interactions, focusing on fungal infection biology. The project develops and expands a laboratory method that enables visualization...
- The National Institute of Allergy and Infectious Diseases awarded The Johns Hopkins University $225,628 on August 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to identify genetic mechanisms of polyene resistance in Candida glabrata using saturating transposon mutagenesis coupled with next-generation DNA sequencing (TN-SEQ). The project will implement TN-SEQ to mutate and barcode every gene in C. glabrata and profile resistance to three approved...
- The National Institute of Allergy and Infectious Diseases awarded the University of Connecticut $251,062 on July 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop antifolate compounds with broad-spectrum antifungal activity targeting invasive fungal infections. The funded research addresses unmet clinical needs in treating opportunistic and emerging fungal pathogens, including Candida auris, Candida albicans, Candida glabrata, Cryptococcus neoformans,...
- The National Institute of Allergy and Infectious Diseases awarded $255,000 to the California Institute of Technology on June 8, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop early-stage technology enabling rigorous and reproducible fungal metatranscriptomics in human vaginal samples. The project addresses the challenge that fungal diseases cost the U.S. an estimated $11 billion annually, yet pathogenesis of many fungal diseases remains poorly...
- The National Institute of Allergy and Infectious Diseases awarded Virginia Polytechnic Institute & State University $198,695 on June 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to support early-stage translational research on repurposing neurokinin-1 (NK1) receptor antagonists as novel antifungal agents. The research addresses the growing challenge of multidrug-resistant invasive fungal infections, particularly Candida auris, Aspergillus fumigatus, and...
- The National Institute of Allergy and Infectious Diseases awarded The Johns Hopkins University $412,324 on June 25, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate whether echinocandin susceptibility can be restored to cross-resistant Candida strains by targeting genes that antagonize FKS gene products. The research uses genome-wide transposon sequencing screens in two cross-resistant derivatives of Candida glabrata to identify candidate genes and...